CSL Limited shares (ASX:CSL) have shown considerable chop in recent years, with the last five years of price action highlighting a market that is uncertain about which direction to take. The company, a stalwart of the ASX and a global leader in biotechnology, finds itself trading at A$239.29 per share, moving closer to the 52wk lows at A$228.61 after a 14.9% decline since the start of this year. This raises the question: Is CSL headed for a retest of support levels, or could it potentially fall outside of the range that has held firm over 5 years?
While CSL boasts a rich history, including an all-time high above $320 in early 2020, the current climate reflects broader sector headwinds and company-specific challenges. The short-term and monthly moving averages are trending downwards, corroborating the bearish sentiment.
Several factors contribute to this subdued performance. The decline in share price began in August 2024, when the company’s FY2024 results initially sparked concern despite reporting a 31% year-over-year revenue growth to US$13.31 billion and a 10% increase in underlying profit to US$2.61 billion. The market reacted negatively to the FY2025 guidance, which projected revenue growth of 5% to 7%. While still positive, this fell short of some analysts’ expectations, triggering a sell-off.
CSL’s financial health remains relatively sound, as evidenced by its valuation metrics. A Price/Earnings (P/E) ratio of 25.68, Price/Book Value of 4.01, Price/Sales of 5.34, and Price/Cash Flow of 28.40 suggest a premium valuation, reflecting the market’s recognition of CSL’s quality and long-term potential. The current ratio of 1.86 and interest coverage of 8.01 indicate strong liquidity and the ability to meet its financial obligations. The company’s bond issuance in March 2024, raising US$1.25 billion to refinance existing debt, was a strategic move that improved its financial flexibility. However, these positive aspects are currently overshadowed by concerns about future growth and market sentiment.
Analysts price targets range from $249 to $345, indicating a potential upside from current levels. However, achieving these targets hinges on CSL’s ability to deliver on its growth strategy and address market concerns. The upcoming earnings report in August 2025 will be crucial. Analysts will be closely scrutinizing the company’s performance and guidance for signs of a turnaround. A failure to meet expectations could trigger further downside pressure, potentially leading to a retest of recent lows. The consensus price target of $310 indicates there is perceived upside from current levels, although time will tell whether further shifts in forecast are required. Analysts, it should be noted, can change their view in an instant.
Top Australian Brokers
- Pepperstone - Trading education - Read our review
- IC Markets - Experienced and highly regulated - Read our review
- eToro - Social and copy trading platform - Read our review
For the time being, CSL’s share price continues to trade above the April lows, although the chart shows the stock continues in a downward channel that began back in August of last year. The upcoming report could prove to be pivotal in determining the next leg for CSL. While the company’s fundamentals remain robust, concerns about growth, coupled with negative market sentiment, have weighed heavily on the stock price.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
